<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02490865</url>
  </required_header>
  <id_info>
    <org_study_id>08.1.2.H8</org_study_id>
    <nct_id>NCT02490865</nct_id>
  </id_info>
  <brief_title>Systemic Bioactivity of Inhaled Nebulized RNS60</brief_title>
  <official_title>Systemic Bioactivity of Inhaled Nebulized RNS60</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Revalesio Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Revalesio Corporation</source>
  <brief_summary>
    <textblock>
      The study aims to determine the effects of nebulized RNS60 on selected biomarkers in the&#xD;
      circulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a double-blind, placebo controlled, parallel design study. Participants will be&#xD;
      randomized to receive 2 daily doses of either nebulised RNS60 or placebo (n=28 per group) for&#xD;
      22 days. On day 19 they will undergo an exercise protocol to induce muscle damage and blood&#xD;
      samples will be taken on days 19, 20, 21 and 23 to determine the effects on CK and hsCRP. ROM&#xD;
      and pain VAS assessments will also be completed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum concentration of creatine kinase (CK)</measure>
    <time_frame>4 days post exercise</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum concentration of highly sensitive C-reactive protein (hsCRP)</measure>
    <time_frame>4 days post exercise</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Systemic Bioactivity of Nebulized RNS60</condition>
  <arm_group>
    <arm_group_label>RNS60</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of nebulized RNS60 to test for systemic bioactivity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of normal saline used as control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RNS60</intervention_name>
    <description>RNS60, 4 ml dose nebulized twice daily</description>
    <arm_group_label>RNS60</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal Saline, 4 ml dose nebulized twice daily</description>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The participant is able to read and understand the Informed Consent Form (ICF), and&#xD;
             understand study procedures.&#xD;
&#xD;
          2. The participant has signed the ICF.&#xD;
&#xD;
          3. Healthy male or female participants aged 18-45 years inclusive. Attempts will be made&#xD;
             to achieve an equal gender ratio through appropriate screening procedures, but a&#xD;
             failure to do so will not preclude analysis of the final data set.&#xD;
&#xD;
          4. BMI between 19 and 27 kg/m2.&#xD;
&#xD;
          5. The participant is, in the opinion of the investigator, healthy on the basis of&#xD;
             medical history and vital signs.&#xD;
&#xD;
          6. Available for follow-up for the duration of the study.&#xD;
&#xD;
          7. Non-smokers (no smoking or use of nicotine replacements (including e-cigarettes) in&#xD;
             the previous month before screening or during the study)&#xD;
&#xD;
          8. Agree to abstain from donating blood during the study.&#xD;
&#xD;
          9. Men and women of reproductive potential who document use of adequate contraception&#xD;
             during the study and for 1 month following the last day of treatment (Day 23)&#xD;
&#xD;
         10. Willing to refrain from taking anti-inflammatory medications during the study&#xD;
             (particularly ibuprofen).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant psychiatric, cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal, endocrine, neurological (particularly myasthenia gravis),&#xD;
             immunological, or haematological disease or abnormality, as determined by the study&#xD;
             physician.&#xD;
&#xD;
          2. History of alcohol, narcotic, benzodiazepine, or other substance abuse or dependence&#xD;
             within the 12 months preceding Visit 1.&#xD;
&#xD;
          3. History of significant musculoskeletal upper limb injury.&#xD;
&#xD;
          4. Participating in regular (â‰¥ 2 times per week) upper body resistance exercise training&#xD;
             within 6 weeks of Visit 1.&#xD;
&#xD;
          5. FEV1 &lt; 80% or FEV1/FEC of &lt; 75%&#xD;
&#xD;
          6. Use of steroids or immunosuppressive/immunomodulating drugs either orally or&#xD;
             parenterally within 3 months of Visit 1.&#xD;
&#xD;
          7. Use of NSAIDs and other OTC medications within 2 weeks of Visit 1.&#xD;
&#xD;
          8. Use of any dietary/nutritional supplements, including vitamins and minerals, in the 2&#xD;
             weeks before Visit 1.&#xD;
&#xD;
          9. Positive urinary pregnancy test.&#xD;
&#xD;
         10. Pregnant or lactating at any point during the study from screening to final visit.&#xD;
&#xD;
         11. Following a weight reducing diet.&#xD;
&#xD;
         12. Currently participating in another clinical trial with an investigational or&#xD;
             non-investigational drug or device, or has participated in another clinical trial&#xD;
             within the 3 months preceding Visit 1.&#xD;
&#xD;
         13. Any condition that, in the investigator's opinion, compromises the participant's&#xD;
             ability to meet protocol requirements or to complete the study.&#xD;
&#xD;
         14. Receipt of blood products or immunoglobin, within 3 months of visit 1.&#xD;
&#xD;
         15. Unable to read and speak English to a fluency level adequate for the full&#xD;
             comprehension of procedures required in participation and consent.&#xD;
&#xD;
        No waivers from the Protocol will be allowed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Surrey Clinical Research Centre</name>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <zip>GU2 7XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>July 2, 2015</study_first_submitted>
  <study_first_submitted_qc>July 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2015</study_first_posted>
  <last_update_submitted>September 18, 2015</last_update_submitted>
  <last_update_submitted_qc>September 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>RNS60</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

